EA202290154A1 - Фармацевтическая композиция для лечения острого миелоидного лейкоза, содержащая ингибитор flt3 и химиотерапевтические агенты - Google Patents

Фармацевтическая композиция для лечения острого миелоидного лейкоза, содержащая ингибитор flt3 и химиотерапевтические агенты

Info

Publication number
EA202290154A1
EA202290154A1 EA202290154A EA202290154A EA202290154A1 EA 202290154 A1 EA202290154 A1 EA 202290154A1 EA 202290154 A EA202290154 A EA 202290154A EA 202290154 A EA202290154 A EA 202290154A EA 202290154 A1 EA202290154 A1 EA 202290154A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
pharmaceutical composition
myeloid leukemia
acute myeloid
chemotherapeutic agents
Prior art date
Application number
EA202290154A
Other languages
English (en)
Russian (ru)
Inventor
Ин Хван Бае
Дзи Йоунг Сонг
Дзае Юл Чой
Йоунг Гил Ахн
Original Assignee
Ханми Фарм. Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ханми Фарм. Ко., Лтд. filed Critical Ханми Фарм. Ко., Лтд.
Publication of EA202290154A1 publication Critical patent/EA202290154A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EA202290154A 2019-06-27 2020-06-25 Фармацевтическая композиция для лечения острого миелоидного лейкоза, содержащая ингибитор flt3 и химиотерапевтические агенты EA202290154A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20190077302 2019-06-27
PCT/KR2020/008258 WO2020262974A1 (ko) 2019-06-27 2020-06-25 Flt3 저해제 및 화학치료제를 포함하는 급성 골수성 백혈병 치료용 약학적 조성물

Publications (1)

Publication Number Publication Date
EA202290154A1 true EA202290154A1 (ru) 2022-03-29

Family

ID=74060307

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202290154A EA202290154A1 (ru) 2019-06-27 2020-06-25 Фармацевтическая композиция для лечения острого миелоидного лейкоза, содержащая ингибитор flt3 и химиотерапевтические агенты

Country Status (11)

Country Link
US (1) US12350265B2 (https=)
EP (1) EP3991733A4 (https=)
JP (1) JP2022538817A (https=)
KR (1) KR20210002015A (https=)
CN (1) CN114650823A (https=)
AU (1) AU2020308814A1 (https=)
CA (1) CA3145391A1 (https=)
EA (1) EA202290154A1 (https=)
IL (1) IL289366A (https=)
MX (1) MX2021015724A (https=)
WO (1) WO2020262974A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101954370B1 (ko) 2018-07-25 2019-03-05 한미약품 주식회사 피리미딘 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물
BR112021016522A2 (pt) 2019-02-22 2021-10-26 Hanmi Pharm. Co., Ltd. Composição farmacêutica para o tratamento da leucemia mieloide aguda
EA202290154A1 (ru) 2019-06-27 2022-03-29 Ханми Фарм. Ко., Лтд. Фармацевтическая композиция для лечения острого миелоидного лейкоза, содержащая ингибитор flt3 и химиотерапевтические агенты
TW202246243A (zh) * 2021-02-26 2022-12-01 美商泰拉生物科學公司 胺基嘧啶化合物及其使用方法
WO2023027966A1 (en) 2021-08-24 2023-03-02 Biomea Fusion, Inc. Pyrazine compounds as irreversible inhibitors of flt3
MX2024008057A (es) 2021-12-30 2024-08-28 Biomea Fusion Inc Compuestos de pirazina como inhibidores de flt3.
WO2023225005A1 (en) 2022-05-17 2023-11-23 Biomea Fusion, Inc. Flt3 combination therapy for cancer and compositions therefor
WO2024206989A2 (en) * 2023-03-30 2024-10-03 Bioventures, Llc Flt3 inhibitors and methods of using the same

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0500492D0 (en) 2005-01-11 2005-02-16 Cyclacel Ltd Compound
US20060281768A1 (en) 2005-06-10 2006-12-14 Gaul Michael D Thienopyrimidine and thienopyridine kinase modulators
AU2007325280B2 (en) 2006-11-28 2011-03-10 Dana-Farber Cancer Institute, Inc. Combination of IAP inhibitors and FLT3 inhibitors
EP2133095A4 (en) 2007-03-05 2012-09-26 Kyowa Hakko Kirin Co Ltd PHARMACEUTICAL COMPOSITION
JP2011500808A (ja) 2007-10-24 2011-01-06 メルク・シャープ・エンド・ドーム・コーポレイション 複素環アミドｔ型カルシウムチャネルアンタゴニスト
FR2926553B1 (fr) 2008-01-23 2010-02-19 Sanofi Aventis Derives d'indole-2-carboxamides et d'azaindole-2- carboxamides substitues par un groupe silanyle, leur preparation et leur application en therapeutique
US20110183975A1 (en) * 2008-10-07 2011-07-28 Yasuhiro Goto Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity
CN101723936B (zh) 2008-10-27 2014-01-15 上海睿星基因技术有限公司 激酶抑制剂及其在药学中的用途
UY32203A (es) 2008-10-29 2010-05-31 Astrazeneca Ab Amino pirimidinas y su uso en terapia
CA2755976C (en) * 2009-03-23 2020-04-07 Ambit Biosciences Corporation Methods of treatment using combination therapy
CN102471339A (zh) 2009-07-15 2012-05-23 雅培制药有限公司 激酶的吡咯并吡啶抑制剂
MX342164B (es) 2010-06-23 2016-09-19 Hanmi Science Co Ltd Derivados de pirimidina fusionados novedosos para la inhibicion de la actividad de tirosina cinasa.
UY33539A (es) * 2010-08-02 2012-02-29 Astrazeneca Ab Compuestos químicos alk
EP4119551A1 (en) 2011-07-27 2023-01-18 Astrazeneca AB 2-(2,4,5-substituted-anilino)pyrimidine compounds
WO2013146963A1 (ja) 2012-03-28 2013-10-03 武田薬品工業株式会社 複素環化合物
WO2014155300A2 (en) 2013-03-28 2014-10-02 Aurigene Discovery Technologies Limited Substitued pyrimidine amine derivatives as tak-1 inhibitors
CN110229142A (zh) 2014-04-04 2019-09-13 希洛斯医药品股份有限公司 细胞周期蛋白依赖性激酶7(cdk7)的抑制剂
EP3778584A1 (en) 2014-06-19 2021-02-17 ARIAD Pharmaceuticals, Inc. Production process of 2-chloro-4-heteroaryl-pyrimidine derivatives
CN106458969A (zh) 2014-08-25 2017-02-22 四川海思科制药有限公司 一种(取代的苯基)(取代的嘧啶)胺基衍生物及其制备方法和药物用途
CN105085489B (zh) 2014-11-05 2019-03-01 益方生物科技（上海）有限公司 嘧啶或吡啶类化合物、其制备方法和医药用途
CA2976752C (en) 2015-02-20 2019-12-17 Daiichi Sankyo Company, Limited Method for treating cancer by combined use
WO2016155655A1 (zh) 2015-04-03 2016-10-06 上海瑛派药业有限公司 Parp抑制剂固体药物剂型及其应用
KR101799781B1 (ko) 2015-07-23 2017-11-22 재단법인 강릉과학산업진흥원 소뼈 추출분말의 제조방법
US10829484B2 (en) 2015-07-28 2020-11-10 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
KR102110573B1 (ko) 2015-08-13 2020-05-13 베이징 한미 파마슈티컬 컴퍼니 리미티드 Irak4억제제 및 이의 용도
AU2016324920B2 (en) 2015-09-14 2022-03-03 Brunangelo Falini Dactinomycin compositions and methods for the treatment of acute myeloid leukemia
US10927418B2 (en) 2015-11-11 2021-02-23 Celator Pharmaceuticals, Inc. Assays and methods for selecting a treatment regimen for a subject with leukemia
CA3017408C (en) 2016-03-15 2025-08-19 Oryzon Genomics, S.A. LSD1 INHIBITOR COMBINATIONS FOR THE TREATMENT OF HEMATOLOGICAL MALIGNITIS
CA3018155A1 (en) 2016-03-29 2017-10-05 Astellas Pharma Inc. Combination therapy for the treatment of acute myeloid leukemia
ES2805976T3 (es) 2016-06-30 2021-02-16 Janssen Pharmaceutica Nv Derivados heteroaromáticos en calidad de inhibidores de NIK
WO2018092020A1 (en) 2016-11-15 2018-05-24 Novartis Ag Dose and regimen for hdm2-p53 interaction inhibitors
US20200039998A1 (en) 2016-12-19 2020-02-06 Epizyme, Inc. Amine-substituted heterocyclic compounds as ehmt2 inhibitors and methods of use thereof
ES2938648T3 (es) 2017-01-17 2023-04-13 Astrazeneca Ab Inhibidores selectivos de JAK1
KR102175710B1 (ko) 2017-01-23 2020-11-06 주식회사 엘지화학 폴리아릴렌 설파이드 수지 조성물
EP3789386A1 (en) 2017-01-26 2021-03-10 Hanmi Pharm. Co., Ltd. Pyrimidine compound and pharmaceutical use thereof
TWI821174B (zh) 2017-02-21 2023-11-11 加拿大商艾普托斯生物科學公司 治療血液惡性腫瘤患者的方法
EP3661511A1 (en) 2017-08-01 2020-06-10 Julius-Maximilians-Universität Würzburg Use of flt3 car-t cells and flt3 inhibitors to treat acute myeloid leukemia
AU2018354423B2 (en) 2017-10-27 2024-11-07 Plexxikon Inc. Formulations of a compound modulating kinases
EP3755703B1 (en) 2018-02-20 2022-05-04 Incyte Corporation N-(phenyl)-2-(phenyl)pyrimidine-4-carboxamide derivatives and related compounds as hpk1 inhibitors for treating cancer
SG11202012425QA (en) 2018-07-13 2021-01-28 Gilead Sciences Inc Pd-1/pd-l1 inhibitors
KR101954370B1 (ko) * 2018-07-25 2019-03-05 한미약품 주식회사 피리미딘 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물
KR102297587B1 (ko) 2018-08-07 2021-09-06 재단법인 대구경북첨단의료산업진흥재단 치환된 n-헤테로아릴 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물
CN113166110B (zh) 2018-12-12 2023-08-11 暨南大学 2-氨基嘧啶类化合物及其应用
WO2020171649A1 (ko) 2019-02-22 2020-08-27 한미약품 주식회사 Flt3 저해제 및 iap 길항제를 포함하는 급성 골수성 백혈병의 치료를 위한 약학적 조합물
BR112021016522A2 (pt) * 2019-02-22 2021-10-26 Hanmi Pharm. Co., Ltd. Composição farmacêutica para o tratamento da leucemia mieloide aguda
KR20200102948A (ko) 2019-02-22 2020-09-01 한미약품 주식회사 Flt3 저해제 및 iap 길항제를 포함하는 급성 골수성 백혈병의 치료를 위한 약학적 조합물
KR20200102949A (ko) 2019-02-22 2020-09-01 한미약품 주식회사 Flt3 저해제 및 저메틸화제를 포함하는 급성 골수성 백혈병의 치료를 위한 약학적 조성물
EA202290154A1 (ru) 2019-06-27 2022-03-29 Ханми Фарм. Ко., Лтд. Фармацевтическая композиция для лечения острого миелоидного лейкоза, содержащая ингибитор flt3 и химиотерапевтические агенты
KR20210038366A (ko) 2019-09-30 2021-04-07 한미약품 주식회사 Flt3 저해제 및 mdm2 저해제를 포함하는 급성 골수성 백혈병 치료용 약학적 조성물
CN115151534B (zh) 2020-02-14 2024-02-06 南京药石科技股份有限公司 白细胞介素-1受体相关激酶(irak)/fms样受体酪氨酸激酶(flt3)的抑制剂、其药物产品及其方法
EP4241773A4 (en) 2020-11-05 2024-10-16 Hanmi Pharm. Co., Ltd. PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF LEUKEMIA WITH FLT3 INHIBITOR
KR20230056331A (ko) 2021-10-20 2023-04-27 한미약품 주식회사 급성 골수성 백혈병의 치료를 위한 FLT3 저해제와 Bcl-2 저해제의 치료 유효적 조합
AU2023372170A1 (en) 2022-11-04 2025-04-24 Hanmi Pharm. Co., Ltd. Novel crystalline form of a pyrimidine compound and pharmaceutical compositions comprising the same and methods of use thereof
WO2024124199A1 (en) 2022-12-10 2024-06-13 Aptose Biosciences Inc. Methods for treating patients with hematologic malignancies
CN121586574A (zh) 2023-05-31 2026-02-27 韩美药品株式会社 髓样激酶组抑制剂的固体分散体和包含所述固体分散体的药物组合物

Also Published As

Publication number Publication date
KR20210002015A (ko) 2021-01-06
EP3991733A1 (en) 2022-05-04
MX2021015724A (es) 2022-05-16
WO2020262974A1 (ko) 2020-12-30
AU2020308814A1 (en) 2022-02-03
CA3145391A1 (en) 2020-12-30
IL289366A (en) 2022-02-01
CN114650823A (zh) 2022-06-21
US20220354842A1 (en) 2022-11-10
JP2022538817A (ja) 2022-09-06
US12350265B2 (en) 2025-07-08
EP3991733A4 (en) 2023-07-05

Similar Documents

Publication Publication Date Title
EA202290154A1 (ru) Фармацевтическая композиция для лечения острого миелоидного лейкоза, содержащая ингибитор flt3 и химиотерапевтические агенты
PH12021551985A1 (en) Pharmaceutical composition comprising flt3 inhibitor and hypomethylating agent for treating acute myeloid leukemia
GEAP202315703A (en) Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer
NZ775660A (en) Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
MX2020011868A (es) Inhibidores de los receptores erbb.
MX2020007947A (es) Inhibidores de erbb/btk.
GEP20247638B (en) Pharmaceutical combination of prmt5 inhibitors
GEP20227359B (en) Substituted bicyclic heterocyclic compounds as prmt5 inhibitors
EA202193015A1 (ru) Ингибиторы cdk
WO2020132661A3 (en) Inhibitors of fibroblast activation protein
MX2024014861A (es) Inhibidor de la prmt5 de tres anillos fusionados que contiene nitrogeno, y metodo de preparacion del mismo y uso farmaceutico del mismo
MX2023002324A (es) Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados.
EA202191984A1 (ru) Фармацевтическая композиция, содержащая ингибитор flt3 и гипометилирующий агент, для лечения острого миелолейкоза
PH12021550713A1 (en) Medicament for the treatment of chronic cough
MX2021007247A (es) Derivados de rapamicina.
MX2024005107A (es) Nuevo uso de compuesto de quinazolinona para el tratamiento de cancer.
MX2025003515A (es) Moduladores de akt1
EA202191170A1 (ru) Комбинированная терапия для лечения гематологических заболеваний
MX2025005474A (es) Farmaco farmaceutico que contiene derivado de heterocicliden acetamida
GEAP202516637A (en) Bicyclic heterocyclic amide inhibitors of na v1.8 for the treatment of pain
PH12020551772A1 (en) Oxo-substituted compound
MX2023005913A (es) Derivados de bencenosulfonamida y usos de los mismos.
EA202190064A1 (ru) Цианотриазоловые соединения и варианты их применения
GEAP202516217A (en) Compounds and compositions as sppl2a inhibitors
EA201992817A1 (ru) Синергетические композиции, содержащие (r)-димирацетам (1) и (s)-димирацетам (2) в нерацемическом соотношении